Fidelity Disruptive Medicine ETF
FMED
12 hedge funds and large institutions have $22.2M invested in Fidelity Disruptive Medicine ETF in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
3.79% less ownership
Funds ownership: 52.43% → 48.64% (-3.8%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
95% less capital inflows, than outflows
Capital inflows: $521K | Capital outflows: $11.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$251K |
| 2 |
Old Mission Capital
Chicago,
Illinois
|
+$228K |
| 3 |
Farther Finance Advisors
San Francisco,
California
|
+$23.4K |
| 4 |
Parallel Advisors
San Francisco,
California
|
+$10K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$9.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$657K |
| 3 |
Virtu Financial
New York
|
-$343K |
| 4 |
Vise Technologies
New York
|
-$234K |
| 5 |
BXM Wealth
Englewood,
Colorado
|
-$213K |
FMED Hedge Fund Activity: Q2 2026 in Review
12 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in Fidelity Disruptive Medicine ETF (FMED) for Q2 2026, worth a combined $22.2M — down 25% from $29.7M a quarter earlier.
Fund positioning in FMED was balanced in Q2 2026: 5 funds opened new positions, 5 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $251K. The largest seller was Wealth Enhancement Advisory Services, exiting entirely with an estimated $9.5M sold.
- 12 institutional investors held Fidelity Disruptive Medicine ETF (FMED) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $22.2M of Fidelity Disruptive Medicine ETF stock for Q2 2026, down 25% quarter-over-quarter.
- 5 funds opened new Fidelity Disruptive Medicine ETF positions in Q2 2026 and 5 closed out, a net change of 0 holders.
- The largest Fidelity Disruptive Medicine ETF buyer in Q2 2026 was Citadel Advisors, an estimated $251K added.
- The largest Fidelity Disruptive Medicine ETF seller in Q2 2026 was Wealth Enhancement Advisory Services, an estimated $9.5M sold.
Based on aggregated 13F filings for Q2 2026.